GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Basilea Pharmaceutica Ltd (XSWX:BSLN) » Definitions » Median PS Value

Basilea Pharmaceutica (XSWX:BSLN) Median PS Value : CHF61.50 (As of May. 12, 2024)


View and export this data going back to 2004. Start your Free Trial

What is Basilea Pharmaceutica Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Basilea Pharmaceutica's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was CHF12.219. Basilea Pharmaceutica's 10-Year median PS Ratio is 5.0331. Therefore, the Median PS Value for today is CHF61.50.

As of today (2024-05-12), Basilea Pharmaceutica's share price is CHF42.95. Basilea Pharmaceutica's Median PS Value is CHF61.50. Therefore, Basilea Pharmaceutica's Price to Median PS Value for today is 0.69.

The historical rank and industry rank for Basilea Pharmaceutica's Median PS Value or its related term are showing as below:

XSWX:BSLN' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.24   Med: 0.47   Max: 0.71
Current: 0.69

During the past 13 years, the highest Price to Median PS Value of Basilea Pharmaceutica was 0.71. The lowest was 0.24. And the median was 0.47.

XSWX:BSLN's Price-to-Median-PS-Value is ranked worse than
50.19% of 259 companies
in the Biotechnology industry
Industry Median: 0.7 vs XSWX:BSLN: 0.69

Basilea Pharmaceutica Median PS Value Historical Data

The historical data trend for Basilea Pharmaceutica's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Basilea Pharmaceutica Median PS Value Chart

Basilea Pharmaceutica Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Median PS Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 152.79 100.96 103.13 100.34 61.50

Basilea Pharmaceutica Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 103.13 - 100.34 - 61.50

Competitive Comparison of Basilea Pharmaceutica's Median PS Value

For the Biotechnology subindustry, Basilea Pharmaceutica's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Price-to-Median-PS-Value falls into.



Basilea Pharmaceutica Median PS Value Calculation

Basilea Pharmaceutica's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=12.219*5.0331
=61.50

10-Year Median PS Ratio is 5.0331.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Basilea Pharmaceutica's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was CHF12.219.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Basilea Pharmaceutica  (XSWX:BSLN) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Basilea Pharmaceutica's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=42.95/61.50
=0.70

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Basilea Pharmaceutica Median PS Value Related Terms

Thank you for viewing the detailed overview of Basilea Pharmaceutica's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Basilea Pharmaceutica (XSWX:BSLN) Business Description

Traded in Other Exchanges
Address
Switzerland Innovation Park, Basel Area, Main Campus, Near Basel, Allschwil, CHE, 4058
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.

Basilea Pharmaceutica (XSWX:BSLN) Headlines

No Headlines